title: Immunolabeling for p16, WT1, and Fli-1 in the assignment of growth phase for cutaneous melanomas.
abstract: Distinction between radial growth phase (RGP) and vertical growth phase (VGP) in cutaneous melanomas is prognostically significant. Despite established morphological criteria, molecular markers to separate RGP and VGP have not been well established. The goal of this study was to investigate associations of p16, WT1, and Fli-1 with RGP-to-VGP progression, by immunohistochemistry. The p16 is a tumor suppressor, whereas WT1 and Fli-1 are transcriptional activators. The authors hypothesized that entry into VGP would be associated with decreased p16 and increased WT1 and Fli-1. Paraffin sections from 18 RGP and 15 VGP melanomas were immunostained with well-characterized antibodies to p16, WT1, and Fli-1. Melanoma growth phases were determined using precodified morphological attributes. In RGP melanomas, p16 was expressed in 15 of 18 (83%), WT1 in 17 of 17 (100%), and Fli-1 at least focally in 6 of 18 (33%). The deep dermal component of VGP melanomas stained positively for Fli-1 in 9 of 14 (64%), strongly for WT1 in 10 of 14 (71%), and strongly for p16 in only 2 of 15 (13%). Observed patterns of WT1 immunopositivity did not support the authors' hypothesis; it is not likely to be a good indicator of VGP. On the other hand, Fli-1 staining trended toward more positive deep tumor compartment staining and p16 to weaker staining in the deep compartment. At present, application of histological criteria remains the best method for assignment of growth phase in melanomas; however, p16 and possibly Fli-1 immunostains may serve as useful adjuncts in morphologically indeterminate cases.
authors: *School of Medicine, University of Virginia, Charlottesville, VA; and Departments of †Pathology; and ‡Surgery, University of Virginia, Charlottesville, VA. Dr Strickler is now with the Department of Dermatology at the St. Lukes-Roosevelt Hospital Center, New York, NY.
authors: Allen G
authors: AG
authors: Strickler
authors: Jochen T
authors: JT
authors: Schaefer
authors: Craig L
authors: CL
authors: Slingluff
authors: Mark R
authors: MR
authors: Wick
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis; D019941:Cyclin-Dependent Kinase Inhibitor p16; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008545:Melanoma / Q000473:pathology*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis / Q000096:biosynthesis*; D051789:Proto-Oncogene Protein c-fli-1 / Q000032:analysis / Q000096:biosynthesis*; D012878:Skin Neoplasms / Q000473:pathology*; D025721:WT1 Proteins / Q000032:analysis / Q000096:biosynthesis*; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; C000614131:CDKN2A protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; C078433:FLI1 protein, human; D009363:Neoplasm Proteins; D051789:Proto-Oncogene Protein c-fli-1; D025721:WT1 Proteins; C583751:WT1 protein, human